IP Group announced that its portfolio company Istesso published encouraging data in the peer reviewed monthly, The Journal of Pharmacology and Experimental Therapeutics, demonstrating its new class of orally administered investigational medicines elicit tissue repair in fibrotic, autoinflammatory and autoimmune conditions. The published data is preclinical and therefore still early stage, but we consider it good news as it provides the initial support to the company’s plans for additional clinical studies for Leramistat, focused on tissue repair and fibrosis. See our February 2025 update note for further background.
Industrials | Comment
Industrials | Comment
Industrials | Comment
Consumer | Comment